Condition: Breast Cancer · Sponsor: Genentech, Inc.
This is a first-in-human, Phase Ia/Ib, dose-escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-0587 (cyclin-dependent kinase-4 \[CDK4\] inhibitor) as a monotherapy and in combination with giredestrant in participants with locally advanced or metastatic estrogen receptor-positive and human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer who have previously progressed during or after CDK 4/6 inhibitor therapy.
This description comes directly from the study's public registry record.
Reference Study ID Number: GO46057 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. only) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| START - Midwest - EDOS | Grand Rapids, Michigan, United States | Recruiting |
| START - San Antonio - EDOS | San Antonio, Texas, United States | Recruiting |
| National Taiwan University Hospital | Taipei, Taipei City, Taiwan | Recruiting |
| National Cheng Kung University Hospital | Tainan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07214662